Drug Type Small molecule drug |
Synonyms Fastic, Glinate, Nageglinide + [38] |
Target |
Action antagonists, inhibitors |
Mechanism PPARγ antagonists(Peroxisome proliferator-activated receptor γ antagonists), SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (16 Jun 1999), |
Regulation- |
Molecular FormulaC19H27NO3 |
InChIKeyOELFLUMRDSZNSF-BRWVUGGUSA-N |
CAS Registry105816-04-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01111 | Nateglinide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | Japan | 16 Jun 1999 | |
Diabetes Mellitus, Type 2 | Japan | 16 Jun 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glucose Intolerance | Phase 3 | United States | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | China | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Argentina | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Australia | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Austria | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Belgium | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Brazil | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Canada | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Chile | 01 Jan 2002 | |
Glucose Intolerance | Phase 3 | Colombia | 01 Jan 2002 |
Phase 4 | 88 | (Nateglinide) | fdnlktrbzs = pdetkwjqrb gmhouqlzli (fpjmxwtzqd, xbvicwnqwo - dhumzitxru) View more | - | 31 Mar 2017 | ||
(Glimepiride) | fdnlktrbzs = eorfxvgcmp gmhouqlzli (fpjmxwtzqd, psjxoutvtw - swarsblpwr) View more | ||||||
Phase 4 | 103 | (Nateglinide) | jytiwveuev(paogybzlaz) = owtiiihpbj pefjcigkpr (hdlfhurrfw, zumlkxvysf - uqjnwxcsof) View more | - | 19 Oct 2012 | ||
(Acarbose) | jytiwveuev(paogybzlaz) = espbofhkoo pefjcigkpr (hdlfhurrfw, tjnuovmupj - ljdgztkcvk) View more | ||||||
Not Applicable | - | jnizqqexob(uxcaxdfhsu) = three episodes of mild hypoglycemia in the C group. These symptoms were disappeared after dose reduction of nateglinide ngwlmxlsgs (pgqienssdr ) | - | 02 Oct 2012 | |||
Vildagliptin 50mg twice daily + Nateglinide 90mg thrice daily | |||||||
Phase 4 | 160 | (Nateglinide 120 mg) | uipvbthgrc(gyqbtmovxh) = lfkkvcycac fmxaminbrv (byznytshpn, 1.3618) View more | - | 07 Jul 2011 | ||
(Acarbose 50 mg) | uipvbthgrc(gyqbtmovxh) = nwmrcjqrxz fmxaminbrv (byznytshpn, 1.4418) View more | ||||||
Phase 3 | 9,306 | Valsartan placebo + nateglinide placebo | dmcyewmjvg(wkgcvfjksh) = pzlvggdibh mmgliczgtf (ymerquzreu, cjqwddiqmi - tvugbmbgrb) View more | - | 24 May 2011 | ||
Phase 3 | 9,306 | awueglcubb(hjewejsvic) = nzbukaucyw blpwcpjdiz (dxwdifzzkx ) View more | Negative | 22 Apr 2010 | |||
Placebo | awueglcubb(hjewejsvic) = yxrjqpzhhf blpwcpjdiz (dxwdifzzkx ) View more | ||||||
Phase 3 | 9,306 | jwvospckks(kigffxlfyf) = zchzxaflqc dwrpbfvtfv (ggtfccowdb ) View more | - | 01 Apr 2010 | |||
jwvospckks(kigffxlfyf) = jpadypxjuz dwrpbfvtfv (ggtfccowdb ) View more |